Johnson & Johnson CFO on Q3 earnings, outlook and more

J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticalsПодробнее

Johnson & Johnson CFO Joseph Wolk on Q3 results: Very well-positioned into 2024 and beyondПодробнее

Johnson & Johnson CFO on Q3 earnings, Covid vaccine boosterПодробнее

Johnson & Johnson CFO on Q3 earnings, outlook and moreПодробнее

J&J CFO Joe Wolk: Anticipating 3% operational growth in 2025 despite 'significant' headwindsПодробнее

Johnson & Johnson CFO on third-quarter earnings resultsПодробнее

Johnson & Johnson CFO talks earnings, vaccinesПодробнее

Johnson & Johnson reports Q3 earnings beat, raises full-year guidanceПодробнее

Johnson & Johnson CFO on Q2 earnings, raising guidance, Covid-19 and moreПодробнее

Johnson & Johnson CFO discusses earnings, profit forecast, vaccines, and talcum powder lawsuitsПодробнее

JNJ pharmaceutical business will be on par with January, but medical device unit to see impact: CFOПодробнее

J&J's Q1 earnings miss was because of Covid-19 vaccine: CFO Joseph WolkПодробнее

Great scientific innovation continues to produce great financial results for our company: J&J CFOПодробнее

Johnson & Johnson beat on Q3 earnings despite inflationary pressuresПодробнее

Watch CNBC's full interview with Johnson & Johnson CFO Joseph WolkПодробнее

J&J CFO on Q2 Earnings, Acquisitions and Product PortfolioПодробнее

J&J CFO Joseph Wolk on Q2 earnings beat: Very pleased with the performance overallПодробнее

Johnson & Johnson stock up, CFO weighs in on earnings, demand, and company outlookПодробнее

Johnson & Johnson CFO on Q2 earnings beatПодробнее

Johnson & Johnson CFO on Q2 earnings, litigation, product pipelineПодробнее